Prognostic evidence of LEF1 isoforms in childhood acute lymphoblastic leukemia

dc.authoridSinem Fırtına / 0000-0002-3370-8545en_US
dc.authorscopusidSinem Fırtına / 16642650000
dc.authorwosidSinem Fırtına / X-8520-2018
dc.contributor.authorErbilgin, Yucel
dc.contributor.authorHatırnaz Ng, Özden
dc.contributor.authorCan, İsmail
dc.contributor.authorFırtına, Sinem
dc.contributor.authorKüçükcankurt, Fulya
dc.contributor.authorKaraman, Serap
dc.date.accessioned2021-04-13T11:30:53Z
dc.date.available2021-04-13T11:30:53Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.description.abstractIntroduction: The lymphoid enhancer factor 1 (LEF1) is a DNA-binding transcription factor that functions in the Wnt signaling pathway. Increased LEF1 activity is associated with progression of several types of cancer including leukemia. Here, we investigated LEF1 isoform expression and genomic variations in acute lymphoblastic leukemia (ALL). Methods: LEF1 isoform expression was evaluated by quantitative real-time PCR in 87 newly diagnosed childhood ALL patients and controls. Moreover, Western blot analysis was performed for detection of LEF1 expression and the hotspot region of LEF1 was screened by deep sequencing. Results: The LEF1 mRNA expression of B cell ALL patients was higher than the controls (LEF1-total P = .011, LEF1-long P = .026). Moreover, B-ALL samples showing higher total LEF1 expression had significantly shorter relapse-free survival (P = .008) and overall survival (P = .011). Although full-length LEF1 expression was similar to the controls in T-ALL, 50% (n = 15) of the ALL patients had increased full-length LEF1 protein expression. Imbalance between short- and full-length LEF1 isoforms may lead to cell survival in ALL. Beside the LEF1 activation, LEF1 gene variations were rarely observed in our cohort. Conclusion: The results indicate that the Wnt pathway may have a pathogenic function in a group of ALL patients and high LEF1-total expression might be a marker for shorter relapse-free survival time in B cell ALL.en_US
dc.identifier.citationErbilgin, Y., Hatirnaz Ng, O., Can, I., Firtina, S., Kucukcankurt, F., Karaman, S., Karakas, Z., Celkan, T. T., Zengin, E., Aylan Gelen, S., Nihal Ozdemir, G., Yildirmak, Y., Dogru, O., Tansel, T., Khodzhaev, K., Toluk, O., Ozbek, U., & Sayitoglu, M. (2021). Prognostic evidence of LEF1 isoforms in childhood acute lymphoblastic leukemia. International journal of laboratory hematology, 10.1111/ijlh.13513. Advance online publication. https://doi.org/10.1111/ijlh.13513en_US
dc.identifier.doi10.1111/ijlh.13513en_US
dc.identifier.endpage11en_US
dc.identifier.pmid33844466en_US
dc.identifier.scopus2-s2.0-85104151982en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1111/ijlh.13513
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1691
dc.identifier.wosWOS:000639287900001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorFırtına, Sinem
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofInt J Lab Hematol.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkeren_US
dc.subjectGene Expressionen_US
dc.subjectPrognosisen_US
dc.subjectLEF1en_US
dc.subjectALLen_US
dc.titlePrognostic evidence of LEF1 isoforms in childhood acute lymphoblastic leukemiaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
46.pdf
Boyut:
1.29 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: